Condition: Kidney Transplantation in Highly Sensitized Patients · Sponsor: Hansa Biopharma AB
The goal of this clinical trial is to learn about the efficacy and safety of imlifidase in highly sensitized paediatric patients, 1-17 years old, with end stage renal disease (ESRD). The main questions it aims to answer are: * Does imlifidase treatment result in crossmatch conversion that enables transplantation? * How is the function of the transplanted kidney? The participants will be hospitalised in accordance with the normal routines for transplanted patients. The patients will receive medication to prevent rejection of the donor kidney, and because such treatment make the body more vulnerable medications to prevent infections.
This description comes directly from the study's public registry record.
Central Contact · +46 46 16 56 70 · clinicalstudyinfo@hansabiopharma.com
Always discuss trial participation with your own doctor first.
| HUS, Helsinki University Hospital | Helsinki, Finland | Withdrawn |
| Robert Debre University Hospital | Paris, France | Recruiting |
| Hospital Unviersitari Vall d'Hebron, Nefrología Pediátrica | Barcelona, Spain | Recruiting |
| Karolinska University Hospital | Huddinge, Stockholm County, Sweden | Recruiting |
| Great Ormond Street Hospital for Children NHS Foundation Trust | London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05753930